Nujiangexathone A, a novel compound from Garcinia nujiangensis, suppresses cervical cancer growth by targeting hnRNPK

Cancer Letters

Volumn 380, Issue 2, 2016, Pages 447-456

  Zhang, Li ^a,b   Feng, Jiling ^a,b   Kong, Siyuan ^a,b   Wu, Man ^a,b   Xi, Zhichao ^a,b   Zhang, Baojun ^a,b   Fu, Wenwei ^a,b   Lao, Yuanzhi ^a,b   Tan, Hongsheng ^a,b   Xu, Hongxi ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b China State Institute of Pharmaceutical Industry   (China)

Author keywords

Cell cycle; Cervical cancer; Garcinia species; hnRNPK; Nujiangexathone A

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MYC PROTEIN; NUJIANGEXATHONE A; PLANT MEDICINAL PRODUCT; PROTEIN P27; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; HNRNPK PROTEIN, HUMAN; PLANT EXTRACT; PROTEASOME; RIBONUCLEOPROTEIN; XANTHONE DERIVATIVE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GARCINIA; GARCINIA NUJIANGENSIS; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; ISOLATION AND PURIFICATION; MEDICINAL PLANT; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYTOTHERAPY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR VOLUME; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GARCINIA; HELA CELLS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RIBONUCLEOPROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978776074     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.07.005     Document Type: Article

References (45)

1. [1] Stewart, B.W., Chapter 5.12. World Cancer Report 2014 World Health Organization, 2014 9283204298.
2. [2] Wild, C.P., Chapter 1.1. World Cancer Report 2014 World Health Organization, 2014 9283204298.
3. [3] Gadducci, A., Barsotti, C., Cosio, S., Domenici, L., Riccardo Genazzani, A., Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol. Endocrinol 27 (2011), 597–604.
4. [4] Waggoner, S.E., Cervical cancer. Lancet 361 (2003), 2217–2225.
5. [5] Man, S., Gao, W., Wei, C., Liu, C., Anticancer drugs from traditional toxic Chinese medicines. Phytother. Res 26 (2012), 1449–1465.
6. [6] Tang, Z.Y., Xia, Z.X., Qiao, S.P., Jiang, C., Shen, G.R., Cai, M.X., et al. Four new cytotoxic xanthones from Garcinia nujiangensis. Fitoterapia 102 (2015), 109–114.
7. [7] Han, Q.B., Xu, H.X., Caged Garcinia xanthones: development since 1937. Curr. Med. Chem 16 (2009), 3775–3796.
8. [8] Xia, Z.X., Zhang, D.D., Liang, S., Lao, Y.Z., Zhang, H., Tan, H.S., et al. Bioassay-guided isolation of prenylated xanthones and polycyclic acylphloroglucinols from the leaves of Garcinia nujiangensis. J. Nat. Prod 75 (2012), 1459–1464.
9. [9] Anderson, N.L., Anderson, N.G., Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19 (1998), 1853–1861.
10. [10] Blackstock, W.P., Weir, M.P., Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17 (1999), 121–127.
11. [11] Feng, X.P., Yi, H., Li, M.Y., Li, X.H., Yi, B., Zhang, P.F., et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 70 (2010), 3450–3462.
12. [12] Merkley, M.A., Weinberger, P.M., Jackson, L.L., Podolsky, R.H., Lee, J.R., Dynan, W.S., 2D-DIGE proteomic characterization of head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg 141 (2009), 626–632.
13. [13] Schaaij-Visser, T.B., Brakenhoff, R.H., Jansen, J.W., O'Flaherty, M.C., Smeets, S.J., Heck, A.J., et al. Comparative proteome analysis to explore p53 pathway disruption in head and neck carcinogenesis. J. Proteomics 72 (2009), 803–814.
14. [14] Thiel, U.J., Feltens, R., Adryan, B., Gieringer, R., Brochhausen, C., Schuon, R., et al. Analysis of differentially expressed proteins in oral squamous cell carcinoma by MALDI-TOF MS. J. Oral Pathol. Med 40 (2011), 369–379.
15. [15] Yan, G., Li, L., Tao, Y., Liu, S., Liu, Y., Luo, W., et al. Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology. Proteomics 6 (2006), 1810–1821.
16. [16] Tian, H.L., Yu, T., Xu, N.N., Feng, C., Zhou, L.Y., Luo, H.W., et al. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway. Cancer Lett 297 (2010), 18–30.
17. [17] Feng, C., Zhou, L.Y., Yu, T., Xu, G., Tian, H.L., Xu, J.J., et al. A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. Int. J. Cancer 131 (2012), 1445–1454.
18. [18] Fu, W.M., Zhang, J.F., Wang, H., Tan, H.S., Wang, W.M., Chen, S.C., et al. Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis. Apoptosis 17 (2012), 842–851.
19. [19] Xu, D., Cao, J., Qian, S., Li, L., Hu, C., Weng, Q., et al. 5k, a novel beta-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis. Invest. New Drugs 29 (2011), 786–799.
20. [20] Matunis, M.J., Michael, W.M., Dreyfuss, G., Characterization and primary structure of the poly(C)-binding heterogeneous nuclear ribonucleoprotein complex K protein. Mol. Cell. Biol 12 (1992), 164–171.
21. [21] Matta, A., Tripathi, S.C., DeSouza, L.V., Grigull, J., Kaur, J., Chauhan, S.S., et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int. J. Cancer 125 (2009), 1398–1406.
22. [22] Pino, I., Pio, R., Toledo, G., Zabalegui, N., Vicent, S., Rey, N., et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41 (2003), 131–143.
23. [23] Wen, F., Shen, A., Shanas, R., Bhattacharyya, A., Lian, F., Hostetter, G., et al. Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma. Ann. Surg. Oncol 17 (2010), 2619–2627.
24. [24] Carpenter, B., McKay, M., Dundas, S.R., Lawrie, L.C., Telfer, C., Murray, G.I., Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer 95 (2006), 921–927.
25. [25] Chen, L.C., Hsueh, C., Tsang, N.M., Liang, Y., Chang, K.P., Hao, S.P., et al. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin. Cancer Res 14 (2008), 3807–3813.
26. [26] Guo, Y., Zhao, J., Bi, J., Wu, Q., Wang, X., Lai, Q., Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J. Hematol. Oncol, 5, 2012, 37.
27. [27] Wu, C.S., Chang, K.P., Chen, L.C., Chen, C.C., Liang, Y., Hseuh, C., et al. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma. Oral Oncol 48 (2012), 516–522.
28. [28] Gao, R., Shah, N., Lee, J.S., Katiyar, S.P., Li, L., Oh, E., et al. Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K. Mol. Cancer Ther 13 (2014), 2930–2940.
29. [29] Strozynski, J., Heim, J., Bunbanjerdsuk, S., Wiesmann, N., Zografidou, L., Becker, S.K., et al. Proteomic identification of the heterogeneous nuclear ribonucleoprotein K as irradiation responsive protein related to migration. J. Proteomics 113 (2015), 154–161.
30. [30] Choi, H.S., Hwang, C.K., Song, K.Y., Law, P.Y., Wei, L.N., Loh, H.H., Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem. Biophys. Res. Commun 380 (2009), 431–436.
31. [31] Michelotti, E.F., Michelotti, G.A., Aronsohn, A.I., Levens, D., Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol. Cell. Biol 16 (1996), 2350–2360.
32. [32] Takimoto, M., Tomonaga, T., Matunis, M., Avigan, M., Krutzsch, H., Dreyfuss, G., et al. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J. Biol. Chem 268 (1993), 18249–18258.
33. [33] Mandal, M., Vadlamudi, R., Nguyen, D., Wang, R.A., Costa, L., Bagheri-Yarmand, R., et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem 276 (2001), 9699–9704.
34. [34] Nagano, K., Masters, J.R., Akpan, A., Yang, A., Corless, S., Wood, C., et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 23 (2004), 1693–1703.
35. [35] Rudolph, B., Saffrich, R., Zwicker, J., Henglein, B., Muller, R., Ansorge, W., et al. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J. 15 (1996), 3065–3076.
36. [36] Vlach, J., Hennecke, S., Alevizopoulos, K., Conti, D., Amati, B., Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15 (1996), 6595–6604.
37. [37] Perez-Roger, I., Solomon, D.L., Sewing, A., Land, H., Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14 (1997), 2373–2381.
38. [38] Leone, G., DeGregori, J., Sears, R., Jakoi, L., Nevins, J.R., Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387 (1997), 422–426.
39. [39] Habelhah, H., Shah, K., Huang, L., Ostareck-Lederer, A., Burlingame, A.L., Shokat, K.M., et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell Biol 3 (2001), 325–330.
40. [40] Daugaard, G., Abildgaard, U., Holstein-Rathlou, N.H., Bruunshuus, I., Bucher, D., Leyssac, P.P., Renal tubular function in patients treated with high-dose cisplatin. Clin. Pharmacol. Ther 44 (1988), 164–172.
41. [41] Anantachoke, N., Tuchinda, P., Kuhakarn, C., Pohmakotr, M., Reutrakul, V., Prenylated caged xanthones: chemistry and biology. Pharm. Biol 50 (2012), 78–91.
42. [42] Wang, X., Chen, W., Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med. Chem 12 (2012), 994–1000.
43. [43] Yi, T., Yi, Z., Cho, S.G., Luo, J., Pandey, M.K., Aggarwal, B.B., et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 68 (2008), 1843–1850.
44. [44] Guo, Q., Qi, Q., You, Q., Gu, H., Zhao, L., Wu, Z., Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin. Pharmacol. Toxicol 99 (2006), 178–184.
45. [45] Qi, Q., You, Q., Gu, H., Zhao, L., Liu, W., Lu, N., et al. Studies on the toxicity of gambogic acid in rats. J. Ethnopharmacol 117 (2008), 433–438.